Lantern Pharma Inc.
NASDAQ:LTRNBiotechnology
-$0.19 today
- Market cap
- $50.14M
- Beta
- 2.32
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$1.41
Volume 0.10M
Average 0.68M
LTRN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Lantern Pharma Inc.NASDAQ: LTRN
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $1.72M fell 47.2% year over year, behind the -34.1% change in trailing-twelve-month research & development. Sequentially, it fell 37.2% from the prior quarter. Over 3 fiscal years it compounded at +10.2% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -47.2% toward the trailing-twelve-month pace of -34.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 11.51M USD
- Year-over-year change
- -28.6%
- 4-year CAGR
- +11.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.51M | -28.6% |
| FY2024 | 2024-12-31 | 16.13M | +35.6% |
| FY2023 | 2023-12-31 | 11.89M | +38.3% |
| FY2022 | 2022-12-31 | 8.6M | +13.6% |
| FY2021 | 2021-12-31 | 7.57M | — |
Research & Development vs competitors
How LTRN compares with its peers on the latest reported figures
- LTRN's LTM Mar 2026 research & development of $9.98M is the 4th highest of the 5 companies compared; the peer median is $16.81M.
- Its year-over-year change of -34.1% is the lowest of 5, against a peer median of +13.9%.
- Over three fiscal years its annual growth of +10.2% compares with a peer median of +14.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.74B | +90463.6% | +15.1% | — | |
| LTM Jun 2026 | $18.74M | -30.0% | -3.0% | 53.4% | |
| LTM Mar 2026 | $14.87M | +36.6% | +1076.5% | — | |
| LTM Mar 2026 | $9.98M | -34.1% | +10.2% | — | |
| LTM Mar 2026 | $5.84M | -8.9% | +13.4% | 392.2% | |
| Peer median (excluding LTRN) | $16.81M | +13.9% | +14.3% | 222.8% | |
Competitors are the stored peer set for LTRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 174.84K | 0 | 0 |
| Gross Profit | 0 | 0 | (174.84K) | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 7.57M | 8.6M | 11.89M | 16.13M | 11.51M |
| Selling, General & Admin | 5.02M | 5.83M | 5.98M | 6.09M | 6.46M |
| Operating Expenses | 12.59M | 14.43M | 17.7M | 22.22M | 17.98M |
| Depreciation & Amortization | 6.76K | 10.08K | 174.84K | 17.28K | 17.28K |
| EBITDA | (12.36M) | (14.05M) | (15.79M) | (20.76M) | (17.1M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (12.59M) | (14.43M) | (17.88M) | (22.22M) | (17.98M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 67.93K | 204.36K | 765.39K | 742.36K | 437.93K |
| Interest Expense | 0 | 204.36K | 0 | 0 | 0 |
| Other Income / Expenses | 228.48K | 172.81K | 1.92M | 1.44M | 859.06K |
| Income Before Tax | (12.36M) | (14.26M) | (15.96M) | (20.78M) | (17.12M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (12.36M) | (14.26M) | (15.96M) | (20.78M) | (17.12M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.13) | (1.31) | (1.47) | (1,930.92) | (1.57) |
| EPS (Diluted) | (1.13) | (1.31) | (1.47) | (1,930.92) | (1.57) |
| Weighted Avg Shares | 10.9M | 10.85M | 10.84M | 10.76M | 10.9M |
| Weighted Avg Shares (Diluted) | 10.9M | 10.85M | 10.84M | 10.76M | 10.9M |
Lantern Pharma Inc.
NASDAQ:LTRN
Intrinsic Alpha fair value
Locked
Current Price
$3.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.